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Abstract
Dent’s disease is characterized by manifestations of proximal tubule dysfunction including hypercalciuria, kidney stones,
proteinuria, rickets and progressively declining kidney function. The diagnosis is based on the presence of low-molecular-
weight proteinuria, hypercalciuria and at least one of the following: nephrocalcinosis, kidney stones, haematuria,
hypophosphataemia or renal insufficiency. Dent’s disease is a hereditary condition that is caused by variants in the CLCN5
gene or the OCRL1 gene and affects only males. Herein, we report on two brothers who were found to have a previously
reported disease-causing variant in the CLCN5 gene. One sibling had nephrocalcinosis, proteinuria and hypercalciuria,
whereas the other sibling was asymptomatic and had normal laboratory findings.
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Introduction
Dent’s disease, first described in 1964 [1], comprises a group of
familial tubular syndromes [2] known to affect approximately
250 families in the world [3]. They often share a common aetiol-
ogy consisting of variants in the CLCN5 gene, which is located
on chromosome Xp11.22 and encodes a lysosomal transport
protein, ClC-5, a chloride channel predominantly expressed in
the kidney [4]. The variant either decreases or abolishes the
function of the chloride channel [5]. Dent’s disease Type 2 is
caused by variants in the OCRL1 gene, which is located on chro-
mosome Xq25 and encodes a phosphatase. To date, Dent’s dis-
ease Type 2 is known to affect approximately 20 patients [6].
Dent’s disease Type 1 and Dent’s disease Type 2 have different
aetiologies but show a similar kidney phenotype. However,
patients with variants in the OCRL1 gene may show extra-renal
manifestations such as mild intellectual impairment, hypotonia
and cataract. Variants in OCRL may also lead to a more severe
phenotype with congenital cataract termed Lowe syndrome [7].
Variants in other genes may, in some patients, cause Dent’s
disease [8].
Dent’s disease is characterized by manifestations of proxi-
mal tubule dysfunction including hypercalciuria, kidney stones,
proteinuria and rickets. In 30–80% of patients, the disease pro-
gresses to end-stage renal disease (ESRD) between the third and
fifth decades of life [9].
Dent’s disease is inherited in an X-linked recessive manner
such that it affects only males. Female carriers are not significantly
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affected [10]. The disease is caused by variants in the CLCN5 gene or
the OCRL1 gene. Treatment is supportive, with a focus on prevent-
ing nephrolithiasis by increasing fluid intake. Thiazide diuretics
may decrease hypercalciuria. However, thiazide administration
may be complicated by sodium wasting and excessive diuresis.
Case report
A 23-year-old Caucasian male was referred from his general
practitioner (GP) to our nephrology outpatient clinic due to pro-
teinuria (2 g/day) and elevated plasma creatinine (109 mmol/L).
At referral, he was asymptomatic. He was known to have
attention-deficit/hyperactive disorder and was being treated
with methylphenidate. A renal biopsy was performed. Light
microscopic examination of medullary tissue showed medul-
lary interstitial fibrosis, tubular atrophy and calcinosis in
medullary tubules (Figures 1 and 2). Immunofluorescence and
electron microscopy of glomeruli did not reveal any specific
changes; in particular, there were no signs of segmental sclero-
sis. Fibrosis was observed in the interstitium.
Physical examination was unremarkable. The patient was
normotensive (125/79 mmHg). Laboratory findings showed ele-
vated plasma creatinine (123 mmol/L), normal plasma glucose
(5.7 mmol/L), elevated haemoglobin (11.3 mmol/L), slightly ele-
vated ionized calcium (1.35 mmol/L) and low parathyroid hor-
mone (1.2 pmol/L). Urine dipstick testing showedþþprotein,
þþblood andþþglucose. Further investigation included 24-h
urine collection, which revealed proteinuria of 1.74 g/day and
hypercalciuria of 10.5 mmol/day, as well as a low amount of cit-
rate in the urine (0.34 mmol/day). On examination 2 months
later, his blood pressure (155/85 mmHg) and plasma creatinine
(154 mmol/L) had increased, and treatment with ramipril (2.5 mg
daily) was initiated. After 3 months, he was hospitalized due to
abdominal pain with fluctuating intensity. A computed tomog-
raphy scan showed calcinosis and small kidney stones, 4 mm in
diameter. In sonographic images, the kidneys appeared slightly
small. The right kidney had a length of 10.3 cm, and the left kid-
ney had a length of 9.9 cm. There were no signs of urinary tract
obstruction. The patient was prescribed thiazide with potas-
sium chloride (2.5 mg daily) to decrease hypercalciuria. Prior to
treatment his plasma electrolytes were normal: potassium
3.8 mmol/L, phosphate 0.67 mmol/L, ionized calcium 1.29 mmol/L
and plasma creatinine 157 mmol/L.
After 2 months, his GP contacted us because the patient had
severe hypokalaemia (2.5 mmol/L) despite administration of
potassium (1500 mg daily) for a few days. It was recommended
that the GP discontinued the administration of thiazide with
potassium chloride and prescribed potassium as well as
increased the dose of ramipril to 10 mg/day.
Proteinuria, hypercalciuria, glycosuria, nephrocalcinosis and
severe hypokalaemia following administration of thiazide in
combination with elevated plasma creatinine are signs of proxi-
mal tubule dysfunction. Urine protein electrophoresis was per-
formed to confirm the diagnosis, and the result showed
elevated b2-microglobulin (80 normal range), urine albumin
(10 normal range) and glycosuria. Sanger sequencing of the
CLCN5 and OCRL genes identified the variant CLCN5 (c.473G>A,
p.Gly158Asp). This variant has previously been reported in three
family members affected by Dent’s disease in a German family
[11]. No variant form of the OCRL gene was identified.
The patient’s brother had no symptoms, but nonetheless under-
went medical evaluation. His blood pressure was 145/85 mmHg.
Laboratory findings were all within normal range: plasma creati-
nine 91 mmol/L, potassium 4.0 mmol/L, phosphate 0.97 mmol/L and
calcium 1.22 mmol/L. The 24-h urine collection presented normal
excretion of calcium, citrate and oxalate. A computed tomography
scan showed neither concretions nor nephrocalcinosis. Predictive
genetic testing identified the same CLCN5 variant in the brother. He
will be followed up in our nephrological outpatient clinic to monitor
future symptoms, which could progress to Dent’s disease.
Discussion
The variant of the CLCN5 gene had previously been reported as
disease-causing. Our patient and his brother had this variant and
did not have any extra-renal manifestations. Before the genetic
analysis was performed, different causes of proximal renal tubu-
lar acidosis with Fanconi syndrome were considered; these
causes can be separated into genetic and acquired disorders. The
acquired disorders may include amyloidosis, multiple myeloma,
paroxysmal nocturnal haemoglobinuria and administration of
drugs, for instance, antiviral therapy [12]. The patient did not
have signs of any of these diseases and had not taken any drugs
other than the methylphenidate prescribed by his GP.
Dent’s disease has been previously reported to be present
already in childhood with asymptomatic proteinuria [13, 14].
The fully expressed clinical disease has been reported in a 3-
Fig. 1. Renal medulla with calcifications (arrows) in the medullary interstitium
and in the thin loops of Henle. Haematoxylin and eosin stain, 200.
Fig. 2. Renal medulla with calcifications. von Kossa stain, 200.
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year old with evident nephrolithiasis progressing to ESRD at the
age of 40 years [15]. Reinhart et al. [16] have reported different
clinical presentations of patients with CLCN5 variants, raising
the possibility that Dent’s disease may occur more commonly,
in less overt forms and possibly without an apparent family his-
tory. In this case, we were suspicious of the diagnosis when the
patient developed severe hypokalaemia following treatment
with thiazide. In retrospect, attention should have been brought
to proximal tubulopathy earlier as the patient was a young
male with glycosuria but normal serum glucose combined with
symptoms of kidney stones and signs of nephrocalcinosis.
Patients with Dent’s disease and glomerular abnormalities
on renal biopsy usually have focal global glomerulosclerosis. The
tubulointerstitial findings are variable and range from normal to
interstitial fibrosis or tubular atrophy [17]. Moulin et al. have
studied eight renal biopsies from patients with Dent’s disease
showing focal hyaline casts, sometimes calcified, which can be
identified at all stages of the disease [18]. In our case, kidney
biopsy 3 years prior to diagnosis showed interstitial calcinosis in
medullary tubules, which may be an early sign of nephrocalcino-
sis. The patient had no symptoms at the time of renal biopsy, but
proteinuria and slightly elevated plasma creatinine (109 mmol/L).
At this point we had not investigated the proteinuria for b2-
microglobulin as it is not routinely performed. If it had showed
low molecular weight proteinuria, the hallmark of Dent’s disease,
we could have diagnosed the patient earlier.
Although Dent’s disease is now well reported and its aetiology
is known, there is still no clear strategy for managing the disease
[19]. No randomized controlled trials have been performed. The
primary goals, however, are to decrease hypercalciuria, to pre-
vent kidney stone formation and nephrocalcinosis, and to delay
progression to ESRD. Thiazide diuretics have been used for many
years to control hypercalciuria and the recurrence of nephroli-
thiasis. Thiazide diuretics have a dual effect on calcium clearance
not produced by most other natriuretic drugs. First, on initial
administration, thiazide diuretics do not enhance calcium excre-
tion in proportion to sodium excretion. Second, on sustained
administration, thiazide diuretics cause a persistent reduction in
calcium excretion by acting on the distal renal tubule, where
CLCN5 is not expressed, enhancing calcium reabsorption [20].
Patients are advised to increase their fluid intake and avoid vita-
min D, as it increases calcium excretion and thereby stone for-
mation. Cebotaru et al. [21] fed a knockout mouse model of Dent’s
disease on a high-citrate diet, which preserved kidney function.
Based on that study, Cebotaru et al. recommended long-term con-
trol of hypercalciuria as an important factor. To our knowledge,
these findings of a high-citrate diet protecting the kidney have
not been translated into human patients yet.
In conclusion, we present a case report on Dent’s disease
involving two brothers with an identical CLCN5 variant, but due
to incomplete penetrance, only one brother has developed symp-
toms so far. Although Dent’s disease is a very rare disorder, it
should be kept in mind in diagnosing male patients who present
with nephrocalcinosis, proteinuria and hypercalciuria with devel-
opment of severe hypocalcaemia on thiazide treatment.
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